Loading...
ABEO logo

Abeona Therapeutics Inc.NasdaqCM:ABEO Voorraadrapport

Marktkapitalisatie US$310.5m
Prijs aandeel
n/a
1Y-3.7%
7D-6.5%
1D0.7%
Portefeuillewaarde
​
Bekijk

Abeona Therapeutics Inc.

NasdaqCM:ABEO Voorraadrapport

Marktkapitalisatie: US$310.5m

Abeona Therapeutics (ABEO) Aandelenoverzicht

Abeona Therapeutics Inc., een biofarmaceutisch bedrijf in een commerciële fase, ontwikkelt gen- en celtherapieën voor levensbedreigende ziekten in de Verenigde Staten. Meer informatie

Beloningen

De winst zal naar verwachting met 70.15% per jaar groeien

Risicoanalyse

Aanzienlijke insider-verkoop in de afgelopen 3 maanden


ABEO Community Fair Values

Create Narrative

See what 43 others think this stock is worth. Follow their fair value or set your own to get alerts.

Analyst Price Targets

View all narratives

Abeona Therapeutics Inc. Concurrenten

Prijsgeschiedenis en prestaties

Overzicht van hoogtepunten, dieptepunten en veranderingen in de aandelenkoersen voor Abeona Therapeutics
Historische aandelenkoersen
Huidige aandelenkoersUS$5.47
52 Week HoogtepuntUS$7.65
52 Week LaagUS$4.00
Bèta1.32
1 maand verandering-8.60%
3 maanden verandering-3.19%
1 Jaar Verandering-3.70%
3 jaar verandering44.33%
5 jaar verandering-81.92%
Verandering sinds IPO-99.90%

Recent nieuws en updates

Recent updates

Seeking Alpha • Nov 10

Abeona Therapeutics: ZEVASKYN Data Key In Gauging Momentum - Why I Hold

Summary Abeona Therapeutics (ABEO) is at a critical juncture, trading near 52-week lows ahead of its first ZEVASKYN revenue update in Q3. ZEVASKYN, a one-time gene therapy for severe skin disorder, faces execution risks but offers potential market share versus established competitor Vyjuvek. ABEO maintains a strong cash position with over two years of runway, but profitability depends on scaling patient treatments and overcoming manufacturing and regulatory hurdles. Despite a discounted valuation and strong analyst ratings, I rate ABEO as HOLD until Q3 results clarify ZEVASKYN's commercial traction and patient conversion rates. Read the full article on Seeking Alpha
Analyse-artikel • Jan 15

Health Check: How Prudently Does Abeona Therapeutics (NASDAQ:ABEO) Use Debt?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Analyse-artikel • Sep 23

Is Abeona Therapeutics (NASDAQ:ABEO) Using Too Much Debt?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Analyse-artikel • May 01

We're Not Very Worried About Abeona Therapeutics' (NASDAQ:ABEO) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analyse-artikel • Jan 04

We're Not Very Worried About Abeona Therapeutics' (NASDAQ:ABEO) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Analyse-artikel • Aug 16

Here's Why We're Watching Abeona Therapeutics' (NASDAQ:ABEO) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analyse-artikel • Mar 31

Can Abeona Therapeutics (NASDAQ:ABEO) Afford To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Oct 19

Abeona: Pivotal Data Readout EB-101 Before Year End Could Boost Shareholder Value

Summary Results from the pivotal VITAL study, using EB-101 for the treatment of patients with RDEB are expected to be released before the end of 2022. Should EB-101 be approved by FDA for RDEB, it would give company a Priority Review Voucher, which could be sold for around $100 million or more to another pharmaceutical company. ABO-102, which is being developed to treat patients with Sanfilippo syndrome type A has been offloaded to Ultragenyx Pharmaceutical for advancement. Abeona has $26 million in cash as of June 30, 2022. It believes enough cash to fund operations until Q2 of 2023, but will likely have to raise cash before or after data from this late-stage study. Abeona Therapeutics (ABEO) is a great speculative biotech play to look into. That's because it is gearing up to report results from its phase 3 pivotal study known as VITAL. This late-stage study is using its cell therapy known as EB-101 for the treatment of patients with recessive dystrophic epidermolysis bullosa (RDEB). Results from this trial are expected any day now before the end of 2022, therefore, this provides traders/investors with a huge catalyst to look forward to. Abeona wants to focus on this program for its pipeline, therefore, it chose to offload ABO-102 (now UX111) for Sanfilippo syndrome type A ((MPS IIIA)) to Ultragenyx Pharmaceutical (RARE). That is, Ultragenyx will be responsible for taking over this program and moving it forward in the clinic. In return, Abeona will be receiving tiered royalties and commercial milestone payments should this drug ultimately be approved by regulators. With proof of concept established with EB-101 in a prior study, plus year-end 2022 data readout of EB-101 for RDEB, these are the reasons why I believe it is a great speculative biotech play to look into. EB-101 Could Possibly Provide A Great Long-Term Durable Treatment Option For RDEB Patients The main program in the pipeline is EB-101, which is being developed for the treatment of patients with recessive dystrophic epidermolysis bullosa (RDEB). RDEB is a terrible skin condition by which there is lack of collagen protein in the skin. It is a condition by which wounds are large and blisters tend to form. Patients with RDEB suffer greatly because of pain and complications which occur because of it. That's not the only problem to consider though for this patient population. The average life expectancy of someone who has it is 50 years of age. There are not currently any cures available for these patients, but there are treatments that attempt to control symptoms and pain. The main problem is that a mutation in the COL7A1 gene doesn't allow the formation of Type VII collagen, which is necessary for the skin to be healthy. EB-101 is a cell therapy which is being developed to provide functional collagen VII to the patient's own cells. The therapy is autologous, that is, cells are extracted from the patient and then transduced with the correct collagen gene necessary for proper formation. The final outcome is a fully formed sheet which is 5 to 7 cell layers thick. EB-101 is eventually applied to the wound in surgery which helps the patient to restore their functionality of COL7A1 gene encoding provided by the cells. In turn, EB-101 holds the potential to heal and provide pain relief for the patient. Even better, it provides a "one and done" scenario whereby it may be possible to avoid daily wound care. Abeona expects that EB-101 could produce estimated cumulative revenues of $1.5 billion over the products life cycle. As I highlighted in the beginning Abeona Therapeutics is currently running its phase 3 VITAL study, which is using EB-101 for the treatment of patients with RDEB. It has been reported that the final patient completed their 6-month follow-up visit for this late-stage trial on October 4, 2022. This means within the next 3 to 4 weeks, investors should get an idea on whether or not this cell therapy succeeds in meeting the co-primary endpoints for this study. This means before the end of 2022, there will be a data readout from this VITAL study which could possibly boost shareholder value. Of course, both co-primary endpoints must be met for this to happen. Developing a treatment for large chronic wounds is not easy, as such, Abeona and the FDA came to an agreement on what the co-primary endpoints need to be in order for EB-101 to be approved for RDEB. The two co-primary endpoints necessary for regulatory approval are: Proportion of chronic wounds with ≥50% healing from baseline at week 24 (Those treated with EB-101 versus those not treated at all with EB-101) Pain reduction at dressing changes assesses by a mean difference in scores using the Wong-Baker FACES scale at week 24 (Treated EB-101 versus untreated EB-101)
Seeking Alpha • Oct 04

Abeona Therapeutics stock continues recent strong run, shares rise ~10%

Shares of Abeona Therapeutics (NASDAQ:ABEO) gained 10.4% to $3.62 in Tuesday mid-day trading, extending a recent strong run which has seen the stock post gains in four of its last five sessions. The stock rose 7.9% yesterday after Cantor Fitzgerald listed the development-stage biotech among four companies in whose planned phase 3 readout it had a "high conviction". The rebound in ABEO shares come after the stock posted a seven-day losing streak towards the end of last month. The company earlier in the day said the last patient had completed their six-month follow-up visit in its phase 3 study of its cell therapy EB-101 for the treatment of recessive dystrophic epidermolysis bullosa, the most severe form of a condition that causes fragile, blistering skin. ABEO plans to report results from the study within the next month. The study, called VIITAL, is expected to serve as a basis for the company's planned approval submission to the U.S. FDA for EB-101, the company said in a statement.
Seeking Alpha • Aug 11

Abeona Therapeutics GAAP EPS of -$2.08, revenue of $1M

Abeona Therapeutics press release (NASDAQ:ABEO): Q2 GAAP EPS of -$2.08. Revenue of $1M. Cash, cash equivalents, restricted cash and short-term investments totaled $26.0 million as of June 30, 2022.  Shares +1.68% PM.
Seeking Alpha • Jul 20

Abeona therapeutics regains compliance with Nasdaq minimum bid price requirement

Abeona Therapeutics (NASDAQ:ABEO) received Nasdaq notification informing it has regained compliance with the minimum bid price requirement. The requirement was met on July 18, 2022.

Rendement voor aandeelhouders

ABEOUS BiotechsUS Markt
7D-6.5%-3.1%-1.6%
1Y-3.7%37.2%12.1%

Rendement versus industrie: ABEO presteerde slechter dan de US Biotechs -sector, die het afgelopen jaar een rendement van 37.2 % opleverde.

Rendement versus markt: ABEO presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 12.1 % opleverde.

Prijsvolatiliteit

Is ABEO's price volatile compared to industry and market?
ABEO volatility
ABEO Average Weekly Movement7.9%
Biotechs Industry Average Movement9.5%
Market Average Movement6.8%
10% most volatile stocks in US Market15.2%
10% least volatile stocks in US Market2.9%

Stabiele aandelenkoers: ABEO heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de US markt.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 8% ) van ABEO is het afgelopen jaar stabiel geweest.

Over het bedrijf

OpgerichtWerknemersCEOWebsite
1974226Vish Seshadriwww.abeonatherapeutics.com

Abeona Therapeutics Inc., een biofarmaceutisch bedrijf in een commerciële fase, ontwikkelt gen- en celtherapieën voor levensbedreigende ziekten in de Verenigde Staten. Het ontwikkelt ZEVASKYN, een autologe, celgebaseerde gentherapie voor de behandeling van patiënten met recessieve dystrofische epidermolysis bullosa. Het bedrijf ontwikkelt ook ABO-503 voor de behandeling van X-gebonden retinoschisis; ABO-504 voor de behandeling van de ziekte van Stargardt; en ABO-505 voor de behandeling van autosomaal dominante optische atrofie.

Abeona Therapeutics Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Abeona Therapeutics zich tot de beurswaarde?
ABEO fundamentele statistieken
MarktkapitalisatieUS$310.51m
Inkomsten(TTM)-US$62.89m
Inkomsten(TTM)US$25.52m
12.3x
P/S-verhouding
-5.0x
Koers/Winstverhouding

Is ABEO overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
ABEO resultatenrekening (TTM)
InkomstenUS$25.52m
Kosten van inkomstenUS$35.70m
Brutowinst-US$10.18m
Overige uitgavenUS$52.71m
Inkomsten-US$62.89m

Laatst gerapporteerde inkomsten

Jun 30, 2026

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)-1.10
Brutomarge-39.90%
Nettowinstmarge-246.42%
Schuld/Eigen Vermogen Verhouding11.7%

Hoe presteerde ABEO op de lange termijn?

Bekijk historische prestaties en vergelijking

Bedrijfsanalyse en status van financiële gegevens

GegevensLaatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse2026/09/15 09:35
Aandelenkoers aan het einde van de dag2026/09/15 00:00
Inkomsten2026/06/30
Jaarlijkse inkomsten2025/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

PakketGegevensTijdframeVoorbeeld Amerikaanse bron *
Financiële gegevens bedrijf10 jaar
  • Resultatenrekening
  • Kasstroomoverzicht
  • Balans
Consensus schattingen analisten+3 jaar
  • Financiële prognoses
  • Koersdoelen analisten
Marktprijzen30 jaar
  • Aandelenprijzen
  • Dividenden, splitsingen en acties
Eigendom10 jaar
  • Top aandeelhouders
  • Handel met voorkennis
Beheer10 jaar
  • Leiderschapsteam
  • Raad van bestuur
Belangrijkste ontwikkelingen10 jaar
  • Bedrijfsaankondigingen

* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Abeona Therapeutics Inc. wordt gevolgd door 18 analisten. 7 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

AnalistInstelling
James MolloyAlliance Global Partners
George ZavoicoB. Riley Securities, Inc.
Kristen KluskaCantor Fitzgerald & Co.